{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T04:28:28Z","timestamp":1794803308771,"version":"4.9.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203316"],"award-info":[{"award-number":["NIHR203316"]}],"id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR301616"],"award-info":[{"award-number":["NIHR301616"]}],"id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012097","name":"Sense About Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T033371\/1"],"award-info":[{"award-number":["MR\/T033371\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/K022202"],"award-info":[{"award-number":["MR\/K022202"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.eclinm.2024.102726","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T19:32:05Z","timestamp":1720639925000},"page":"102726","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5984-8696","authenticated-orcid":false,"given":"Riccardo","family":"De Giorgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Koychev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda I.","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Cowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine J.","family":"Harmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-952X","authenticated-orcid":false,"given":"Maxime","family":"Taquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2024.102726_bib1","series-title":"Glucagon-like peptide-1 receptor agonists. StatPearls","author":"Collins","year":"2024"},{"issue":"6676","key":"10.1016\/j.eclinm.2024.102726_bib2","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1126\/science.adn4691","article-title":"Obesity meets its match - 2023 breakthrough of the year","volume":"382","author":"Couzin-Frankel","year":"2023","journal-title":"Science"},{"issue":"10296","key":"10.1016\/j.eclinm.2024.102726_bib3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"issue":"10403","key":"10.1016\/j.eclinm.2024.102726_bib4","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0140-6736(23)01479-4","article-title":"Oral semaglutide: an OASIS from injectables","volume":"402","author":"Manjoo","year":"2023","journal-title":"Lancet"},{"issue":"10401","key":"10.1016\/j.eclinm.2024.102726_bib5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(23)01182-0","article-title":"A\u00a0new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena","volume":"402","author":"Bain","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.102726_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102726_bib7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 3","key":"10.1016\/j.eclinm.2024.102726_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/dom.14487","article-title":"Recent developments in GLP-1RA therapy: a review of the latest evidence of efficacy and safety and differences within the class","volume":"23","author":"Bain","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102726_bib9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102726_bib10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1474-4422(20)30231-3","article-title":"Brain insulin resistance in Alzheimer's disease and related disorders: mechanisms and therapeutic approaches","volume":"19","author":"Kellar","year":"2020","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102726_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","article-title":"Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease","volume":"28","author":"Nowell","year":"2023","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.eclinm.2024.102726_bib12","article-title":"Possible mechanisms underlying the effects of glucagon-like peptide-1 receptor agonist on cocaine use disorder","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102726_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am J Geriatr Psychiatry"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102726_bib14","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/13543784.2021.1951702","article-title":"Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential","volume":"30","author":"Flintoff","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"6661","key":"10.1016\/j.eclinm.2024.102726_bib15","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.adk5720","article-title":"Hot weight loss drugs tested against addiction","volume":"381","author":"Leslie","year":"2023","journal-title":"Science"},{"issue":"Pt B","key":"10.1016\/j.eclinm.2024.102726_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.neuropharm.2018.01.048","article-title":"Cognitive dysfunction and metabolic comorbidities in mood disorders: a repurposing opportunity for glucagon-like peptide 1 receptor agonists?","volume":"136","author":"Mansur","year":"2018","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102726_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3673","article-title":"Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: a systematic review and network meta-analysis","volume":"39","author":"Tian","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.eclinm.2024.102726_bib18","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1136\/bmj.p2906","article-title":"GLP-1 receptor agonists: European drug regulator asks makers for evidence of self-harm","volume":"383","author":"Cohen","year":"2023","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.eclinm.2024.102726_bib20","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/brainsci13111503","article-title":"GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach","volume":"13","author":"Arillotta","year":"2023","journal-title":"Brain Sci"},{"issue":"22","key":"10.1016\/j.eclinm.2024.102726_bib21","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1001\/jama.2023.16620","article-title":"As semaglutide's popularity soars, rare but serious adverse effects are emerging","volume":"330","author":"Ruder","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102726_bib22","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records","volume":"11","author":"Xie","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"10.1016\/j.eclinm.2024.102726_bib23","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102726_bib24","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102726_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"15","key":"10.1016\/j.eclinm.2024.102726_bib26","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.102726_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101737","article-title":"Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials","volume":"55","author":"Verma","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2024.102726_bib28","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.2147\/DMSO.S312527","article-title":"An overview of similarities and differences in metabolic actions and effects of central nervous system between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose Co-Transporter-2 Inhibitors (SGLT-2is)","volume":"14","author":"Wen","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102726_bib29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1186\/s12888-022-04163-z","article-title":"Temporally ordered associations between type 2 diabetes and brain disorders - a Danish register-based cohort study","volume":"22","author":"Wimberley","year":"2022","journal-title":"BMC Psychiatry"},{"issue":"15","key":"10.1016\/j.eclinm.2024.102726_bib30","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024003055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024003055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:04:27Z","timestamp":1778904267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024003055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":29,"alternative-id":["S2589537024003055"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102726","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102726","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102726"}}